Neeha Sinai Borker

Neeha Sinai Borker


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
NBNeeha Sinai Borker
Neeha Sinai Borker
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
SSSeemadri Subhadarshini
Seemadri Subhadarshini
RARifat Aara
Rifat Aara
MJMohit Kumar Jolly
Mohit Kumar Jolly
RNRadhika Nair
Radhika Nair
Metastatic cancer is the final frontier in disease progression with few avenues of treatment open to patients. The failure of therapeutic options at the end-stage disease is confounded by the presence of diverse clones in the metastatic tumor which contributes to intratumoral heterogeneity (ITH), resulting in intrinsic and acquired drug resistance. We aim to elucidate the contribution of ITH to the development of metastasis with a focus on the origins and molecular mechanisms driving ITH, as well as the clinical and technical challenges of acquiring and studying metastatic cohorts in which we can investigate this phenomenon. Bioinformatic approaches that could help in silico analysis will be discussed, which could shed light on how to design new therapeutic strategies for metastatic cancer and give hope to patients living under the shadow of the sword of Damocles.

5 September 2025 in Aquatic Ecology
Verified
Journal Article
Open access
PDF file
SDStephen Jonah Dias
Stephen Jonah Dias
NBNeeha Sinai Borker
Neeha Sinai Borker
AYAshish Kumar Yadav
Ashish Kumar Yadav
JDJonathan D’cOsta
Jonathan D’cOsta
ABAtul Sinai Borker
Atul Sinai Borker
PPParesh C. Porob
Paresh C. Porob
The diet of the smooth-coated otter (Lutrogale perspicillata) was assessed in a representative agro-ecosystem complex called “Khazan Lands”, situated within the human-dominated estuarine landscape of the Zuari River of Goa, India. This was achieved by analyzing undigested prey remains from 815 fecal (spraint) samples. Overall, fish dominated otter diet (Percentage Biomass, BIO% = 59%; Relative Frequency of Occurrence, RFO% = 49%), followed by shrimp (BIO% = 37%; RFO% = 42%) and crabs (BIO% = 3%; RFO% = 8%). Other prey groups, including insects, molluscs, amphibians, birds, and mammals, were present in minor quantities (BIO% = < 1%; RFO% = 2%). Shrimp consumption was dominant during the winter (BIO% = 80%; RFO% = 58%) and pre-monsoon seasons (BIO% = 56%; RFO% = 54%), whereas fish dominated during the monsoon (BIO% = 90%; RFO% = 63%) and post-monsoon seasons (BIO% = 79%; RFO% = 56%). 22 fish families were recorded in the diet of the species, with Cichlidae dominating throughout the year (seasonal RFO% = 32–45%). Otters largely consumed small and medium sized fish (< 200 mm) (seasonal RFO% = 81–87%), whereas larger fish (> 200 mm) were consumed less frequently (seasonal RFO% = 13–19%). The composition of economically significant prey (fish, shrimp, and crabs) was high (RFO% = 97%), whereas that of economically insignificant prey (molluscs, birds, amphibians, insects, and mammals) was low (RFO% = 3%). Furthermore, the occurrence of high-value fish families was marginally higher (seasonal RFO% = 50–62%) than low-value families (seasonal RFO% = 38–50%). Our observations suggest an opportunistic feeding habit by the species and a considerable overlap between resources exploited by fisherfolk and L. perspicillata. This study highlights the adaptability of this species, and the importance of Khazans for otter populations in the unprotected, human-dominated estuarine landscapes of Goa, India.

27 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NBNeeha Sinai Borker
Neeha Sinai Borker
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
SSSeemadri Subhadarshini
Seemadri Subhadarshini
RARifat Aara
Rifat Aara
MJMohit Kumar Jolly
Mohit Kumar Jolly
RNRadhika Nair
Radhika Nair
Metastatic cancer is the final frontier in disease progression with few avenues of treatment open to patients. The failure of therapeutic options at the end-stage disease is confounded by the presence of diverse clones in the metastatic tumor which contributes to intratumoral heterogeneity (ITH) resulting in intrinsic and acquired drug resistance. We aim to elucidate the contribution of ITH to the development of metastasis with a focus on the origins and molecular mechanisms driving ITH, as well as the clinical and technical challenges of acquiring and studying metastatic cohorts in which we can investigate this phenomenon. Bioinformatic approaches that could help in silico analysis will be discussed which could shed light on how to design new therapeutic strategies for metastatic cancer and give hope to patients living under the shadow of the sword of Damocles.

28 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RARifat Aara
Rifat Aara
NBNeeha Sinai Borker
Neeha Sinai Borker
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
SSSeemadri Subhadarshini
Seemadri Subhadarshini
VSVp Snijesh
Vp Snijesh
RNRadhika Nair
Radhika Nair
Metastatic breast cancer (mBC) remains an incurable disease with limited treatment options, highlighting the need for novel therapeutic approaches. Combination therapy with chemotherapeutic agents along with targeted therapy are the most common methods of treatment used in the terminal stages of the disease. Eventual development of resistance to these approaches, leading to fatal outcomes suggests the presence or emergence of a heterogenous population of cells intrinsically resistant to commonly used regimens. Previous work identified a heterogeneous population of metastatic tumor cells with distinct molecular characteristics driven by Macc1 (Metastasis Associated in Colon Cancer 1) overexpression, which could be targeted by lovastatin (transcriptional inhibitor of Macc1). Building on this foundation, the efficacy of lovastatin in targeting metastatic cells with high Macc1 expression was evaluated in lung metastasis, and the regulatory pathways governing Macc1 expression and lovastatin treatment in mBC were investigated. The expression of Macc1, in breast cancer biopsies provides insights into the intra and inter tumor heterogeneity of the Macc1 gene and its correlation with disease outcomes. While some studies suggest synergistic effects between statins and chemotherapeutic agents, comprehensive evaluations of various combinations and their therapeutic outcomes are still needed. The therapeutic efficacy of lovastatin combined with chemotherapy to determine the most effective treatment regimen that maximizes tumor cell ablation demonstrated that lovastatin can effectively ablate the chemoresistant tumor cells in mBC. The translational implications of this research will identify patient subgroups that may benefit most from statin-chemotherapy combinations that could support the repurposing of statins as cost-effective adjuvant therapies for mBC.

9 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
PSPratyush Kumar Sahoo
Pratyush Kumar Sahoo
NBNeeha Sinai Borker
Neeha Sinai Borker
RARifat Aara
Rifat Aara
RNRadhika Nair
Radhika Nair
Breast cancer therapy has advanced substantially over the past two decades, yet disease recurrence and metastatic progression remain the leading causes of mortality. Resistance in hormone receptor-positive (HR+), HER2-positive, and Triple-negative (TNBC) disease is conventionally treated as three separate, each driven by its own escape route. This review suggests that resistance across all three subtypes instead converges on a shared, limited set of adaptive programs: epithelial-mesenchymal plasticity, cancer stem cell enrichment, metabolic rewiring, and microenvironment-mediated immune evasion. We trace the stage-wise clinical trajectory and dominant point of failure within each subtype, then examine how large-cohort genomics, single-cell transcriptomics, circulating tumour DNA, and machine learning have exposed this convergence, and the barriers still limiting its clinical use. To move beyond a purely mechanistic argument, we present an exploratory analysis stratifying overall survival within each subtype by which adaptive program dominates the resistant tumour. EMT enrichment in TNBC, immune evasion in HR-positive disease, and metabolic rewiring in HER2-positive disease. Although based on modest cohorts, this pattern suggests the four programs are genuinely different drawing on a shared cellular toolkit, rather than interchangeable descriptions of the same biology, and supports testing metabolic-program enrichment as a maintenance biomarker in HER2-positive disease. Closing the gap between mechanistic knowledge and clinical practice will require replacing subtype-exclusive resistance biomarkers with subtype anchored program-specific panels deployed alongside the standard clinical panel, shifting management from a model that reacts to resistance toward one that anticipates it.